文献速递胸部肿瘤头颈与中枢神经肿瘤

脑脊液基因分型与奥希替尼治疗EGFR突变NSCLC软脑膜转移的疗效及耐药关联

Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC.
PubMed 文献 · J Thorac Oncol · 2020-10-26

本研究纳入EGFR突变晚期NSCLC软脑膜转移患者,队列1(n=45)在奥希替尼首次给药前进行脑脊液和血浆基因分型,队列2(n=35)在奥希替尼进展并诊断LM时进行脑脊液基因分型。脑脊液基因分型对EGFR敏感突变的灵敏度在队列1为93.3%(42/45),队列2为97.1%(34/35)。脑脊液基因分型提示对奥希替尼的异质性反应,并揭示了奥希替尼失败时LM的遗传特征。

要点

  • 脑脊液基因分型对EGFR敏感突变灵敏度高(队列1 93.3%,队列2 97.1%)。
  • EGFR exon 19 deletion较exon 21 L858R中位iPFS更长(11.9 vs 2.8月,p=0.02)。
  • 脑脊液T790M阳性者中位iPFS显著长于阴性者(15.6 vs 7.0月,p=0.04)。

核心结论

  • 脑脊液基因分型提示EGFR突变NSCLC软脑膜转移患者对奥希替尼的异质性反应,并揭示奥希替尼失败时的遗传特征。

研究设计与样本

  • 队列1纳入45例EGFR突变晚期NSCLC软脑膜转移患者,在奥希替尼首次给药前进行脑脊液和血浆基因分型。
  • 队列2纳入35例奥希替尼进展并诊断软脑膜转移患者,进行脑脊液基因分型。
  • 脑脊液循环肿瘤DNA接受下一代测序。

主要发现

  • 队列1中,EGFR exon 19 deletion患者中位颅内无进展生存期(iPFS)高于exon 21 L858R突变患者(11.9 vs 2.8月,p=0.02)。
  • 脑脊液T790M阳性患者中位iPFS显著长于T790M阴性患者(15.6 vs 7.0月,p=0.04)。
  • 并发CDK4突变(2.8 vs 11.6月,p=0.002)和CDKN2A突变(2.5 vs 9.6月,p=0.04)伴EGFR敏感突变者中位iPFS更低。
  • 队列2发现可能的EGFR相关和EGFR非依赖耐药机制,包括C797S突变、MET失调和TP53合并RB1共现。
  • 脑脊液T790M丢失患者中位iPFS短于T790M保留患者(7.4 vs 13.6月,p=0.01)。

临床怎么用

  • 对EGFR突变NSCLC软脑膜转移患者,可考虑脑脊液基因分型以评估奥希替尼疗效异质性。
  • 脑脊液T790M状态、EGFR突变亚型及共突变(如CDK4、CDKN2A)可能有助于风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with NSCLC with leptomeningeal metastases (LM) presented dismal prognosis. Cerebrospinal fluid (CSF) is suggested as a medium of liquid biopsy of LM. However, the clinical implications of CSF genotyping on treatment outcomes remained elusive. METHODS: Patients with EGFR-mutated advanced NSCLC with LM were included: cohort 1, patients with LM who were treated with osimertinib with CSF and plasma genotyping performed before the first dosing of osimertinib (baseline, n = 45); cohort 2, CSF genotyping on progression on osimertinib and development of LM (the progression event on osimertinib is the diagnosis of LM, n = 35). Circulating tumor DNA in CSF underwent next-generation sequencing. RESULTS: Sensitivity of CSF genotyping for EGFR-sensitizing mutations was 93.3% (42 of 45) and 97.1% (34 of 35) in cohorts 1 and 2, respectively. In cohort 1, patients with EGFR exon 19 deletion had higher median intracranial progression free survival (iPFS) than those with EGFR exon 21 L858R mutation (11.9 versus 2.8 mo; p = 0.02). Median iPFS was significantly longer in patients with T790M-positive CSF genotyping (15.6 mo) than T790M-negative CSF (7.0 mo, p = 0.04). Concurrent CDK4 (2.8 versus 11.6 mo, p = 0.002) and CDKN2A (2.5 versus 9.6 mo, p = 0.04) mutation with EGFR-sensitizing mutations indicated lower median iPFS. Patients with T790M-negative CSF, EGFR exon 21 L858R mutation, concurrent FGF3 alteration, and over first-line osimertinib had shortened iPFS. In cohort 2, possible EGFR-related and EGFR-independent resistance mechanisms were found including C797S mutation, MET dysregulation, and TP53 plus RB1 co-occurrence. Patients with loss of T790M in CSF had a shorter median iPFS (7.4 mo) compared with those with reserved T790M (13.6 mo, p = 0.01). CONCLUSIONS: Genotyping of CSF indicated heterogeneous response to osimertinib and revealed the genetic characteristic of LM on osimertinib failure in patients with EGFR-mutated NSCLC diagnosed with LM.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Zheng MM, Li YS, Tu HY, et al. Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC. J Thorac Oncol. 2020. PMID: 33122107. doi:10.1016/j.jtho.2020.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。